How ZIDABACTUM™ Helps Combat Hospital-Acquired Infections Like VAP and cIAI
Hospital’s approaches to treating ICU infections are being revolutionized by ceftazidime and avibactam injection. ZIDABACTUMTM, a potent, next-generation intravenous antibiotic, is proudly marketed and distributed by Aarokiyam. It was created mainly to combat ventilator-associated pneumonia (VAP) and complicated intra-abdominal infections (cIAI), which are hospital-acquired illnesses, particularly when resistance is high.
Why Advanced Treatment Is Needed for Hospital-Acquired Infections
Gram-negative bacteria that are resistant to drugs are frequently the source of illnesses like VAP and cIAI in critical care. Among them are:
Klebsiella pneumoniae
Pseudomonas aeruginosa
Enterobacter species
These pathogens resist most antibiotics, making treatment failures common and dangerous. The need for an ICU-grade antibiotic like ZIDABACTUM™ has never been more urgent.
What Is ZIDABACTUM™?
The IV fixed-dose combination ZIDABACTUMTM contains:
The antibiotic ceftazidime (2 g) is a broad-spectrum cephalosporin.
The non-β-lactam β-lactamase inhibitor avibactam (0.5 g) is used.
Ceftazidime and Avibactam Injection work together to neutralize enzymes that break down antibiotics, which enables ceftazidime to eradicate even bacteria that are resistant to it.
The Function of ZIDABACTUMTM
Ceftazidime kills bacteria by breaking down their cell walls.
Beta-lactamases, such as KPC, AmpC, and some OXA enzymes, are inhibited by avibactam.
This combination restores the power of ceftazidime against resistant pathogens.
It covers strains of E. coli, Enterobacteriaceae, and carbapenem-resistant bacteria.
When other medications fail, ZIDABACTUMTM is the recommended ICU-grade antibiotic because of this mechanism.
Evidence and Clinical Trials
The use of ceftazidime and avibactam injection in actual intensive care unit care is supported by numerous studies.
REPROVE Trial
Studied VAP in ventilated ICU patients.
ZIDABACTUM™ matched meropenem in effectiveness and safety.
RECLAIM Trial
Focused on cIAI patients.
ZIDABACTUM™ + Metronidazole achieved >90% cure rates.
Worked well even in drug-resistant infections.
Meta-analyses
Showed high bacterial eradication in HAP/VAP.
Fewer renal complications than some carbapenems.
How ZIDABACTUM™ Benefits ICU Patients
ZIDABACTUM for VAP is ideal because:
Acts quickly in severe lung infections.
Offers a wide coverage range for Gram-negative bugs.
Works where many standard antibiotics fail.
Helps avoid overuse of carbapenems (antimicrobial stewardship).
Reduces mortality in ventilated patients.
In short, ZIDABACTUM™ is a powerful hospital-acquired pneumonia treatment.
Recommended Dosing Protocol
Standard adult dose for normal renal function:
2.5 g IV (Ceftazidime 2 g + Avibactam 0.5 g)
Administered every 8 hours over a 2-hour infusion.
For cIAI:
Use with Metronidazole 500 mg IV every 8 hours.
Renal adjustment required: Dose varies with creatinine clearance.
Note: Consult medical advisors or the hospital’s antibiotic instructions at all times.
Safety and Side Effects
ZIDABACTUMTM has a good tolerance. The side effects are minor and controllable.
Common side effects:
Headache
Nausea
Diarrhea
Infusion site redness
Rare but serious risks:
Hypersensitivity
Clostridium difficile diarrhea
Elevated liver enzymes
Its safety profile is comparable to that of other ceftazidime and avibactam injections, with fewer nephrotoxic issues.
Why Aarokiyam Recommends ZIDABACTUM™
ZIDABACTUMTM is promptly available for hospitals and critical care units thanks to Aarokiyam.
We support:
Rapid procurement and delivery.
Clinical dosing tools and literature.
Hospital training and pharmacovigilance.
Antibiotic stewardship programs for safer usage.
Aarokiyam provides more than just medication when it comes to ZIDABACTUM for VAP or cIAI; we provide support and trust.
About ZIDABACTUM ™ In Short
ZIDABACTUM™ is a Ceftazidime and Avibactam injection for resistant ICU infections.
It’s approved for hospital-acquired pneumonia treatment and cIAI.
ZIDABACTUM for VAP delivers clinical success in ventilated patients.
In Indian hospitals, Aarokiyam supplies this intensive care unit-grade antibiotic.
Supports antimicrobial stewardship by offering carbapenem-sparing therapy.
Available in 2.5 g fixed-dose vials for IV infusion.
Offers rapid action, safety, and broad Gram-negative coverage.
What Readers Often Want to Know
What if meropenem fails?
ZIDABACTUM™ is your next best option.
Is it proven in real patients?
Yes, through large Phase III trials and real-world evidence.
Can it help in septic ICU patients?
Yes, especially when infections are Gram-negative and MDR.
What if my hospital lacks stock?
Contact Aarokiyam. We offer prompt logistical assistance
Conclusion
For clinicians treating VAP, cIAI, and other ICU infections, ZIDABACTUM™ provides fast, reliable, and targeted therapy. Even against resistant bacteria, the combination of ceftazidime and avibactam injection guarantees widespread action.
This ICU-grade antibiotic stands out as a preferred option due to its evidence-based support and trust among hospitals. When you work with Aarokiyam, you’re selecting a whole clinical treatment rather than just an antibiotic.
Need supply or guidance? Contact Aarokiyam today. We’ll help you deliver life-saving care when it matters most.